Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549076 | 0.91 | MEN1 (0.79) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| SCHEMBL7101378 | 0.88 | CYP19A1 (0.81) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| SCHEMBL11193886 | 0.88 | CYP2D6 (0.56) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| Piperazine SCHEMBL28229145 | 0.80 | MEN1 (0.96) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| SCHEMBL27485345 | 0.80 | MEN1 (0.96) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| SCHEMBL13600073 | 0.79 | CHRM2 (0.53) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| SCHEMBL2794662 | 0.78 | MEN1 (1.00) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| SCHEMBL219432 | 0.78 | MEN1 (1.00) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| SCHEMBL15093686 | 0.77 | MEN1 (0.62) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| SCHEMBL9251253 | 0.76 | MEN1 (0.72) | MEN1KMT2ACYP2D6CYP19A1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8945514-B2 | Contrast agents for magnetic resonance imaging | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-02-03 | — | — | US | disclosed |
| EP-1729818-B8 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | CENTRE NAT RECH SCIENT (FR) | 2010-02-17 | — | — | EP | disclosed |
| EP-1729818-B1 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | CENTRE NAT RECH SCIENT (FR) | 2009-09-23 | — | — | EP | disclosed |
| US-20070218010-A1 | Contrast Agents for Magnetic Resonance Imaging | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-09-20 | — | — | US | disclosed |
| EP-1729818-A2 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | Centre National de la Recherche Scientifique (CNRS) (FR) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094903-A2 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070218010-A1 | Contrast Agents for Magnetic Resonance Imaging | MAG, SLC40A1, FABP7 | MEN1 12/4885KMT2A 1289/4885CYP2D6 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.